Implications Of Part D For Mentally Ill Dual Eligibles: A Challenge For Medicare
Authors:
- 1 March 2006
- journal article
- Published by Health Affairs Publishing, LLC in Health Affairs
- Vol. 25 (2) , 491-500
Abstract
Through the Part D drug program, Medicare has assumed responsibility for the prescription drug needs of beneficiaries and, consequently, for an important component of mental health treatment: psychotropic drugs. Managing the prescription drug benefits of mentally ill dual eligibles could challenge this new program. Efforts to balance quality assurance and cost-effectiveness will be complicated by this population's vulnerability and high level of health care need, the uncertainties surrounding optimal psychotropic drug use, and the economic incentives of prescription-only insurers. We discuss the details and policy implications of this challenge.Keywords
This publication has 22 references indexed in Scilit:
- Effectiveness of Antipsychotic Drugs in Patients with Chronic SchizophreniaNew England Journal of Medicine, 2005
- Mental Health Policy and Psychotropic DrugsThe Milbank Quarterly, 2005
- Medicare As A Catalyst For Reducing Health DisparitiesHealth Affairs, 2005
- Medicaid Policies To Contain Psychiatric Drug CostsHealth Affairs, 2005
- Do new prescription drugs pay for themselves?Journal of Health Economics, 2005
- Prescription Drugs And The Changing Patterns Of Treatment For Mental Disorders, 1996–2001Health Affairs, 2005
- Evidence-Based Medicine In The United States—De Rigueur Or Dream Deferred?Health Affairs, 2005
- Long-term Outcomes of Initial Antidepressant Drug Choice in a "Real World" Randomized TrialArchives of Family Medicine, 1999
- Drug Use in the Nursing HomeAnnals of Internal Medicine, 1995
- Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with SchizophreniaNew England Journal of Medicine, 1994